PMC10352934_01
Poorly cohesive adenocarcinoma (yellow arrows) admixed with abundant tumor-infiltrating lymphocytes (red arrows) in subperitoneal connective tissue (scale 50 mum).
cro-2023-0016-0001-530965_F01.jpg
PMC10352934_01_cro-2023-0016-0001-530965_F01.jpg
F1
She underwent an upper endoscopy with a biopsy finding of a poorly cohesive gastric adenocarcinoma and strong immune infiltration, as shown in Figure 1.
Preserved expression of mismatch repair proteins (MLH1, PMS2, MSH2, MSH6) on immunohistochemistry. MHL1 (a); PMS2 (b); MSH2 (c), and MSH6 (d) (scale 50 mum).
cro-2023-0016-0001-530965_F02.jpg
PMC10352934_01_cro-2023-0016-0001-530965_F02.jpg
F2
Pathology reported a poorly cohesive, poorly differentiated carcinoma with a preserved expression of mismatch repair proteins on immunohistochemistry, as shown in Figure 2.
Comparison of the patients' imaging studies (computerized topographies) from December 2020 prior to immunotherapy and January 2023 with immunotherapy (created with BioRender.com).
cro-2023-0016-0001-530965_F03.jpg
PMC10352934_01_cro-2023-0016-0001-530965_F03.jpg
F3
The patient achieved complete clinical response in January 2023 and remains in complete remission until the present day (more than 1 year and 6 months), as shown in Figure 3.